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(DDTC; 10 mM) on ischaemic preconditioning (cycles of 5 minutes global 
ischaemia followed by 5 minutes of reperfusion prior to the index regional 
ischaemia) and TN Fa (0.5 ng/ml) pre-treatment (7 minutes followed by 1 O 
minutes washout) on 30 minutes regional ischaemia (index ischaemia) 
followed by 2 hours reperfusion in the Langendorff perfused rat heart. Infarct 






MANUSCRIPT ACCEPTED FOR PUBLICATION: 
2001 Relation of Cyclic Nucleotide Ratios to lschaemic and 
Reperfusion Injury in Nitric Oxide Treated Rat Hearts. 
EF du Tait, James J Meiring, Lionel H Opie. 
Accepted for publication in the Journal of Cardiovascular 
Pharmacology 
ARTICLES SUBMITTED FOR PUBLICATION: 
2001 lschaemic and Pharmacologic Preconditioning in Girardi Cells 
and in C2C12 Myotubes - Induce Mitochondrial Uncoupling 
Jan Minners, Lydia Lacerda, Joy McCarthy, James J Meiring, 
Derek M Yellon, Lionel H Opie, Michael N Sack 
Circulation Research, 2001; In press 
CONFERENCES: POSTER/ ORAL PRESENTATION 
2000: TNFa. Promotes Tolerance against lschaemic Damage in 
Myocytes - Evaluation of the Putative Role of a NFK B Activated 
Cell Survival Programme; Congress of the South African Heart 
Association, 27 November 2000, University of Stellenbosch, 
South Africa 
17 
Tf'JFO:-Promotes Tolerance against lschaemic Damage in 
Myocytes - Evaluation of the Putative Role of a NFK B Activated 
Cell Survival Programme; 3rd Annual Zeneca Research Day, 
05 September 2000, University of Stellenbosch, South Africa 
2000: TNFa. Promotes Tolerance against lschaemic Damage in 
Myocytes - Evaluation of the Putative Role of a NFK B Activated 
Cell Survival Programme. 2]1h Annual Research Day, 
05 October 2000, University of Cape Town, South Africa 
1999: Role of the KATP-channel in the Cardioprotection by Nitric Oxide 
Donors, EF du Toit, J Meiring, J McCarthy, LH Opie. 
The 3th International Congress on Cardiovascular 
Pharmacotherapy, Amsterdam; Netherlands - 28 March to 
01 April 1999; 
Abstract published (# 189) in Cardiovascular Drugs and 
Therapy: Vol 13 (1 ), March 1999 
1998: The Relation of Tissue Cyclic Nucleotide Ratios to lschaemic / 
Reperfusion Injury in Nitric Oxide Donor Treated Rat Hearts. 
The 25th Annual Research Day of the Department of Medicine 
October 1998, University of Cape Town, South Africa 
18 
Relat1cm- c5f- T1ssue- cycllc Nucleot1ae Rat1os to lscfiaem1c / 
Reperfusion Injury in Nitric Oxide Donor Treated Rat Hearts. 
EF Du Toit, J Meiring, J McCarthy, LH Opie. 
The 52nd Congress of the Physiology Society of South Africa, 
Rustenburg, September 1998 
1998: Relation of Tissue Cyclic Nucleotide Ratios to lschaemic / 
Reperfusion Injury in Nitric Oxide Donor Treated Rat Hearts. 
EF Du Toit, J Meiring, J McCarthy, LH Opie. 
The 161h World Congress of the International Society for Heart 
Research, Greece; 
Abstract published (# 323) in the Journal of Molecular and 
Cellular Cardiology: May 1998, pA83 
19 




The pleiotropic cytokine tumour necrosis factor alpha (TNFa) is produced by 
the heart in response to the ischaemic preconditioning (PC) stimulus. We 
hypothesised that this endogenously produced peptide may play a role in 
activating the ischaemic PC mediated tolerance towards a subsequent 
ischaemic insult in muscle cells. To test this and to delineate the downstream 
signalling cascades mediating this programme we developed classic PC 
protocols in adherent mature murine C2C12 myotubes and in human cardiac 
derived Girardi cell lines. The C2C12 myotubes were preconditioned using 
either one hour of simulated ischaemia (SI) or the PC-mimetic adenosine (0.1 
mM) or TNFa (0.5 ng/ml) followed by one hour of reoxygenation followed by 
an eight hour SI insult. Cell viability was assessed by measuring lactate 
dehydrogenase (LOH) release. Simulated ischaemia (SI), PC, adenosine and 
TNFa activated the PC programme and increased cell viability by 40±3%, 
28±5% and 36±4% respectively compared to the SI controls (p<0.005 in all 
experiments, n~4 x 6 well plates in all groups). Cell viability was also 
evaluated by the measurement of propidium iodide uptake on flow cytometry. 
Preconditioning and TNFa enhanced cell viability with a reduction in 
propidium iodide uptake by 28% and 41 % respectively versus the ischaemic 
controls. To evaluate whether TNFa activation of the nuclear regulatory 
protein nuclear factor kappa B (NFK B) mediates this myocyte protection, the 
NFK B antagonists diethyldithiocarbamate (DDTC 1 OmM) or sodium salicylate 
(SA 1 OOµM) were co-administered with TN Fa. The myocyte protective effect 
21 
of TNFa was significantly decrease with both antagonists, although not 
completely inhibited/blocked (DDTC - attenuated cell viability by 62±6% and 
SA by 45±5% compared to the TNFa preconditioned cells (p<0.05 vs SI 
controls and p<0.05 vs TNFa PC, with either antagonists). To confirm these 
data, TNFa was used as a PC-mimetic in the isolated Langendorff perfused 
rat heart (Langendorff) preparation . Infarct size was used as the end point. In 
parallel with cell culture studies, TNFa again conferred preconditioning 
induced cardioprotection with partial abrogation of these effects with the 
pharmacological antagonists of NFK B. Thus, TNFa administration mimics the 
cytoprotective effects of ischaemic PC in cardiac, skeletal myocytes and in the 
isolated perfused rat heart. Moreover, these data support the role of TNFa 
production as an endogenous paracrine / autocrine signalling peptide which 
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A~ INTRC>DUCTION---- - - ---~ -
1. Preconditioning in the Heart 
Most solid organs including the heart can be protected from ischaemic injury 
through pre-emptive programming called 'preconditioning•.1 This phenomenon 
was first described by Murry, Jennings and Reimer at Duke University in 
1986. At the time, it was assumed that repetitive short periods of myocardial 
ischaemia would have a cumulative deleterious effect on the heart resulting in 
progressive cell necrosis. Reimer and colleagues designed an experiment to 
explore the relative contribution of high energy phosphate depletion and 
catabolite accumulation on lethal cell injury in the canine myocardium. They 
found that repetitive brief episodes of regional ischaemia in anaesthetised 
dogs resulted in an attenuation of the reduction of adenosine triphosphate 
(ATP) levels during a subsequent prolonged ischaemic insult. This 
preservation of ATP was associated with a reduction in the size of the 
myocardial infarction compared to dogs not exposed to initial transient 
repetitive ischaemic insults. This phenomenon which they termed 'ischaemic 
preconditioning' was accompanied by ATP preservation and infarct size 
reduction.1 It is known that the protection afforded by preconditioning 
ischaemia is apparent immediately following the preconditioning trigger but 
wanes after 1-2 hours. This is referred to as 'classical' preconditioning or the 
first window of protection. In 1993 Yellon and colleagues reported that after 
12-24 hours following the preconditioning ischaemic 'trigger', a delayed phase 
of myocardial protection is induced which although not as powerful as the 
early phase, is more prolonged and lasts up to 72 hours.2,3 This delayed 
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preconditioning or the 'second window of protection' (SWOP). It is likely that 
these temporally distinct cyto-protected periods are mediated by different 
intracellular regulatory events even though they share the same 
preconditioning 'triggers'. 3-5 The current paradigm being that the 'classic' 
preconditioning programme is predominantly activated via post-translational 
modifications of peptides with associated sequelae in the cell. In contrast the 
delayed protection is proposed to be initiated at the pre-translational level. 
The classic preconditioning 'triggers' include transient coronary occlusion, 
brief periods of low-flow ischaemia, adenosine, opioids or bradykinin 
signalling, vigorous p-adrenergic stimulation or via cycles of calcium depletion 
and repletion.6-9 
2. A Historical Perspective of Research on Preconditioning 
2. 1. The Energetic Hypothesis 
An energetic hypotheses to explain PC was the original mechanism proposed 
and has recently been revisited. This hypothesis regarding ATP metabolism in 
preconditioning was based on the early studies of Murry , Jennings and 
Reimer in 1986.1 These investigators showed that four periods of five minutes 
of coronary occlusion, each separated by five minutes of reperfusion, .led to a 
reduction in infarct size following a subsequent 40 minutes occlusion from 
30% of the area of risk in control animals to 7% in dogs exposed to the 
preconditioning protocol. The level of creatine phosphate was also reported to 
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be higher in preconditioned hearts during the first 10 minutes of ischaemia. ------- - ---- --- - - ---· ~- - - ---- ---
Murry et al demonstrated that preconditioning resulted in less accumulation of 
glycolytic products, including lactate, during ischaemia. These data suggest 
that the preconditioning trigger results in a reduced rate of glycolysis and of 
ATP hydrolysis in the subsequent ischaemic insult. Studies also revealed 
attenuation in the development of intracellular acidosis following 
preconditioning.10 Sequelae of this intracellular environment are postulated to 
lead to a reduction in ischaemia induced sodium and calcium loading on the 
basis of a limitation of sodium-proton exchange and sodium-calcium 
exchange during ischaemia following the PC 'trigger'. The paradigm 
suggesting a preservation of ATP and a reduction of glycolysis · as the 
compensatory metabolic responses to the preconditioning trigger are probable 
incomplete. This was recently illustrated by Fryer et al, who demonstrated that 
ischaemic preconditioning (IPC) significantly increased the rate of ATP 
synthesis in rat hearts compared to non-preconditioned ischaemic hearts.11 
They also showed that 5-Hydroxydecanoate (5-HD), a putative mitochondrial 
ATP-sensitive potassium channel blocker partially attenuated the preservation 
of ATP synthesis when it was administered before IPC. Fryer et al's findings 
of improved rates of ATP synthesis in mitochondria isolated from 
preconditioned hearts are consistent with the mechanism that regulation of 
matrix volume is an essential element in the regulation of mitochondrial 
energy production, and matrix expansion secondary to mitochondrial KArP 
opening which has been postulated to activate electron transport and 
stimulate mitochondrial metabolism.12, 13 Furthermore glucose transport into 
cells is a tightly regulated process that responds to hormonal and other stimuli 
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glucose transport could be important for the cardioprotective effects of brief 
intermittent periods of ischaemia and reperfusion or ischaemic 
preconditioning. Previously it was shown that preconditioning reduced the 
production of lactate with an attenuation of the fall in pH during the sustained 
ischaemia, suggesting that glucose utilisation is decreased during ischaemia 
in preconditioning.10 However, in potential contrast to this hypothesis Tong et 
al reported that preconditioning stimulates glucose uptake and that this 
increased uptake was not blocked by wortmannin .14 The translocation of 
GLUT 4 to the plasma membrane was also observed in rat hearts exposed to 
preconditioning. Moreover, Tong and colleagues showed that preconditioning 
stimulates phosphorylation of protein kinase B (PKB) and increases glucose 
uptake in a p38 MAP Kinase dependent manner. This increased glucose 
uptake would be postulated to support maintenance of ATP synthesis as 
reported above. In conclusion the metabolic perturbation in the 
preconditioning programme has not been fully clarified and requires additional 
work. 
2.2. Cell Surface Ligands and G-Protein Coupled Receptors 
Signal transduction pathways activated by the precondition 'trigger' have 
received greater scientific attention than the energetic hypothesis and a larger 
body of data has been generated in this arena. Here several lines of evidence 
suggest a role for a number of endogenous paracrine mediators, which are 
released during the brief period of ischaemia. These ligands act on local 
receptors, as triggers of both classical and delayed preconditioning. Various 
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of substances such as adenosine, acetylcholine, catecholamines, angiotensin 
II, bradykinin, endothelin and opioids.3, 15, 16 The relative importance of these 
triggers seems to be dependent on the species and the end-points of 
protection studied. 9, 17 A common signalling event downstream of these 
triggers is that they are coupled to a pertussis toxin sensitive inhibitory G-
proteins (Gi) receptor. It has been proposed that activation of these Gi-protein 
coupled receptors by various ligands in turn results in activation of protein 
kinase C (PKC) which is thought to be an important intermediate regulatory 
kinase in the signal transduction pathway of ischaemic preconditioning. 9, 16 In 
addition, Gi may mediate other potentially protective mechanisms, such as 
direct inhibition of L-calcium channels and activation of ATP-sensitive 
potassium channels. 
2.3. Activation of Kinases 
Downey and colleagues have proposed that protein kinase C (PKC) plays a 
major role in the signal transduction of preconditioning. PKC is thought to play 
an important role in transmitting the effects of several agonists linked to 
phospholipase C and the phosphatidyl inositol systems.18-20 PKC has 
several isoforms of which a few may be crucial in preconditioning.21 It is 
believed that adenosine A 1 receptor stimulation activates the a-protein kinase 
C isoform. Some studies have supported the hypothesis originally proposed 
by Downey that IPC could be blocked by pretreatment with specific PKC 
inhibitors and the substitution of IPC with PKC activators mimics the infarct 
limiting effects of IPC. The time course of classical preconditioning also 
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following activation .22 However, the putative peptide end-effector(s) of 
preconditioning which are phosphorylated during the activation of the PKC 
has yet to be determined. It is also likely that other protein kinases, in parallel 
with or following activation by PKC may play a role in classic Pc.23 Another 
downstream target of PKC-dependent signalling during the development of 
PC is the Mitogen Activated Protein Kinase (MAPK) superfamily, which 
includes 3 major subfamilies: the p44/p42 MAPKs (Extracellular Regulated 
Kinases, ERKs), the p38 MAPKs and the p46/p54 MAPKs (Janus Kinase 
Janus Kinases, JNKs).18,24,25 Studies have shown that PC activates all of 
the 3 MAPKs subfamilies. Chelerythrine abolished the activation of p44/p42 
MAPKs that indicated that MAPK are downstream of PKC. Overexpression of 
certain PKC isoforms also leads to the activation of p44/p42 MAPKs.25 
2.4. Transcription Factors 
The recruitment by the PC stimulus of PKC and certainly other as-yet-
unidentified kinases are thought to lead to the activation of transcription 
factors that govern the expression of the cardioprotective genes responsible 
for delayed PC. The first transcription-regulator element to be identified as an 
integral component of PC response was nuclear factor-KB (NFK B),4 which is 
known to transactivate for e.g. Inducible Nitric Oxide Synthase (iNOS), COX-2 
and aldose reductase gene expression.3,26,27 Xuan et al demonstrated that 
ischaemic PC induces rapid activation of NFK B and that this event' can be 
mimicked by infusing NO donors in the absence of ischaemia.4 Inhibition of 
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effects of PC indicating that NFK B plays a critical role in the genesis of 
delayed PC. The ischaemic PC-induced activation of NFK B was blocked by 
treatment with reactive oxygen species agonist, L-NA, MPG, and LO-A, 
indicating that the cellular mechanism whereby ischaemic PC activates NFK B 
involves the formation of No28-30 and Reactive Oxygen Species (ROS)31 
and the subsequent activation of Protein Kinase C (PKC) - and Protein 
Tyrosine Kinase (PTK) -dependent signalling events.22,32,33 Subsequent 
studies have shown that ischaemic PC induces both serine and tyrosine 
phosphorylation of IKBa (the cytosolic chaperone of NFK B) concomitant with 
PKC-dependent activation of IKKa and IKKp, suggesting that a dual 
mechanism accounts for the activation of NFK B during ischaemic PC. 3 In 
addition, activating protein 1 (AP-1) has been found to be activated by brief 
myocardial ischaemia in rats and by overexpression of PKCc in 
cardiomyocytes.34 Whether this transcription factor plays a functional role in 
the development of PC response remains to be elucidated. It seems likely that 
the upregulation of iNOS, COX-2 and other co-mediators after PC stimulus 
involves simultaneous activation of multiple stress-responsive transcription 
factors acting in an additive or synergistic manner. 
2.5. KArP Channels - A Common Denominator/Mediator of 
Preconditioning 
A number of ligands and signalling pathways have been proposed to be 
involved in mediating the cardioprotective effect of IPC, as described above. 
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.__ _____ Mornov:e[,_evidence suggests that the ATP-sensitive-potassiom- channer(RITT 
channel) is an important component of this phenomenon and may serve as a 
mitochondrial end effector/mediator in this process.6, 13,35-37 A number of 
KArP channel openers have been shown to produce a beneficial effect on the 
myocardium in numerous models of ischaemia and KArP channel activation 
has been demonstrated to be a key component of IPC. Authors have shown 
that two KArP channel antagonists, glibenclamide and sodium 5-HD blocked 
the protection produced by IPC and also demonstrated that the KArP channel 
openers, aprikalim, diazoxide and nicorandil mimick the beneficial effect of 
IPC by reducing infarct size. Infarct size is considered the gold standard in 
defining the phenomenon of IPC. There is however a lot of speculation 
concerning the role of the sarcolemmal versus mitochondrial KArP channels in 
conferring this cardioprotection.6 KArP channel openers that work on both for 
example pinacidil, cromakalim and P-1075 have mimicked the 
cardioprotection of IPC. It is hypothesised that opening of the mitochondrial 
KArP channel can result in the following phenotypic consequences: membrane 
depolarisation, matrix swelling, enhanced respiration and reduced calcium 
overload.12 In addition, numerous investigators believe that activation of the 
mitochondrial KArP channel results in ROS production, which act as 
intracellular signalling intermediates to modulate downstream cardioprotective 
events.38,39 Despite all of the studies to date, the mechanistic consequences 
of mitochondrial KArP channel activation in the IPC programme require 
additional investigation.40 
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2.6. Alternative Strategies 
The majority of investigation concerning preconditioning has focused on the 
study of G-protein receptor coupled signalling pathways.9 However the 
biology of the cytoprotective programme directing preconditioning remains 
elusive. A question arising is whether G-protein independent receptor 
mediated pathways could play a role in orchestrating the preconditioning 
programme. Furthermore, investigation of alternative signalling pathways 
could identify novel events in the cytoprotective programme. In this regard a 
parallel innate biological phenomenon that could promote cytoprotection 
against ischaemia has recently been recognised.41,42 The process has been 
postulated to be a component of the primative innate immune system. 
3. Innate Immunity - A Potential Component of the Preconditioning 
Programme? 
The innate or natural (non-specific) immune system is the primitive activation 
of cellular events to protect the host against adverse events, including the 
invasion of pathogens. These adaptive mechanisms include the production of 
heat (fever) and the activation of an the inflammatory response which involves 
the action of several molecules including histamines, kinins, cytokines, 
chemokines, neutrophils and mast cells among others to inactivate/destroy 
pathogens.43 These innate responses not only destroy pathogens, but also 
prime cells to resist subsequent attack and regulate additional components of 
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11-------t.he_ immune _ response.- -To- activate- innate immunity - phylogen-etically-
conserved receptors, termed pattern-recognition receptors that have the 
ability to recognise specific pathogen-associated molecular patterns are 
evident in myeloid and non-myeloid cells.44 Examples of the pathogen 
associated molecular pattern include the lipopolysaccharides of Gram-
negative organisms and the teichoic acids of Gram-positive organisms.45 
One of the more interesting examples of a pattern-recognition receptor is the 
recently described Toi/nuclear factor (NF)-KB host defence pathway that was 
first described in the fruit-fly Drosophila.46 There is substantial evidence 
demonstrating mediators and effectors of the innate immune response, 
including proinflammatory cytokines, nitric oxide and chemokines can be 
endogenously produced in the adult mammalian heart (cardiomyocytes) in 
response to challenges with classical pathogen-associated molecular 
patterns, such as lipopolysaccharides and viral particles.42 Moreover, it has 
recently been demonstrated that the heart also expresses two pattern-
recognition receptors for pathogen-associated molecular patterns namely 
CD14 and TLR-4.44 Recent observations suggest that TLR-4 is critical for 
lipopolysaccharide-mediated activation of proinflammatory cytokine 
expression in the adult mammalian heart. These observations provide 
presumptive evidence for a functionally intact innate immune system in the 
heart. Medzhitov et al were the first to show that constitutively active TLR-4 
induces the activation of NFK s.47 TLR-4 can also induce c-Jun NH2 -
terminal kinase (JNK). TLR's may serve as pro-inflammatory receptors in cell 
types without a dedicated immune function. Injured human and · murine 
myocardium exhibit focal areas of intense TLR4 expression. Microorganisms 
36 
.._ _____ ,are- not--the only aGtivators -of -the innate- immunity receptors, buC also 
endogenous signals that originate from injured cells that emanate "danger 
signals" can activate this immune response. Oxidative stress during 
ischaemia is known to induce cell death by apoptotic and necrotic pathways 
and to trigger pro-inflammatory signalling pathways that activate NFK B and 
AP-1 transcription factors.48 Hypothetically, then the ischaemia in the 
preconditioning 'trigger' may activate the innate immune programme. To 
evaluate this, we reviewed the literature to establish whether known activators 
of innate immunity have been demonstrated to activate the preconditioning 
phenotype. One activator of innate immunity (i.e. endotoxin)49 and one apical 
factor directing innate immunity (i.e. TNFa) has been shown to mimic delayed 
preconditioning.50 These effects are discussed below. 
4. Endotoxins in the Second Window of Protection (SWOP) 
A phenomenon called endotoxin tolerance has been described where a 
subset of endotoxin driven responses are down regulated after an initial 
exposure to endotoxin.51 This phenomenon is proposed to provide protection 
from the uncontrolled immunological activation during acute endotoxic shock. 
This endotoxin tolerance syndrome shares a remarkably similar pattern to that 
of ischaemic preconditioning. This similarity is supported by the fact that 
endotoxin tolerance has been shown to promote tolerance to brain ischaemia, 
with attenuated thermal responses and reduced mortality in some species. 52 
Similarly pretreatment of rats with endotoxin 24 hours before regional 
ischaemia results in a reduction in infarct size similar to that found with 
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delayed preconditioning. Endotoxin pretreatment in vivo increases the 
mitochondrial respiratory capacity in rat hepatocytes. Mitochondrial 
biogenesis and the subsequent increase in both enzymatic scavenging of 
superoxide anion is a central feature of endotoxin-mediated tolerance to 
oxidative stress.53 Delayed preconditioning involved the production of 
protective proteins including Manganese superoxide dismutase (Mn-SOD).3 
Further knowledge on tolerance mechanisms is necessary in order to achieve 
a comprehensive view of this phenomenon. Cardioprotection by ischaemic 
preconditioning and by lipopolysaccharides is associated with a reduction in 
TNFa, following the ischaemia/reperfusion injury.49 It is believed that 
lipopolysaccharides (LPS) induced ecto-5'-nucleotidase activity and 
subsequently results in increased production of adenosine which could then 
provide cardioprotection. In addition to causing a time-dependent induction of 
TN Fa, LPS also induce IL-1 ~ and MnSOD mRNA content in rat heart. LPS 
also causes upregulation of the expression of intercellular adhesion molecule-
1 and P-selectin. Endotoxins can activate macrophages, monocytes and 
cardiac myocytes, which then display enhanced cytotoxic activity and 
synthesis of proinflammatory cytokines including TNFa. As TNFa is 
pleiotropic with diverse effects that include cytoprotection and apoptosis, a 
question that could arise is whether this cytokine can trigger the 
preconditioning cytoprotective programme? 
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11--------v,- TNFa-in -Second Window of Preconditioning-
In order to answer the above question, investigators have studied whether 
TNFa can trigger the second window of protection (SWOP). The second 
window of ischaemic preconditioning is closely related to de nova synthesis of 
proteins such as heat shock proteins, and the endogenous free radical 
scavenger mitochondrial manganese superoxide dismutase (Mn-SOD). 
Interestingly TNFa and interleukin 1 (IL-1) are known as potent inducers of 
Mn-SOD mRNA.54 TNFa and IL-1 are both reported to be involved in the 
radioresistance cytoprotection induced by sublethal ionizing radiation or 
lipopolysaccharide. These cytokines are also reported to be involved in the 
delayed cardioprotection against ischaemia / reperfusion injury in rat and 
canine models. Yamashita reported that TNFa and IL-1 induce a biphasic 
cardioprotection, which corresponds to the activation of Mn-SOD mRNA. In a 
separate study Yamashita and colleagues demonstrated that the induction of 
TN Fa and IL-1 ~ during exercise plays an important role in the exercise -
induced cardioprotection through the activation and or the induction of MN-
SOD. In a subsequent study Yamashita and colleagues demonstrated that 
they could abrogate delayed ischaemic preconditioning in vivo by 
administration of antisense to Mn-SOD and via pretreatment with neutralising 
antibodies to TNFa and IL-1 ~. They concluded that both TN Fa and IL-1 ~ are 
involved in the ischaemia-induced delayed cardioprotection via the induction 
and activation of Mn-SOD. The signalling pathway of TN Fa and IL-1 ~ trans-
activation of Mn-SOD was recently shown to occur via activation of NFK-B. 
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a-------6.- TNJ;a and Classic Preconditioning ___ _ 
Data regarding TNFa in classic PC is limited. In brief, Meldrum et al 
demonstrated that ischaemic preconditioning or adenosine pretreatment 
reduces TNF peptide in the myocardium following a subsequent ischaemia-
reperfusion injury. 55 Heusch and colleagues demonstrated that serum 
TNFa levels are elevated in response to IPC trigger and then remained 
unchanged in rabbits subjected to IP or LPS compared to the control group 
where there was a marked increase during the ischaemia-reperfusion.49 
Another study where the role of TNFa in preconditioning was studied was 
when Hallenback and colleagues investigated the role of TNFa in hypoxic 
preconditioning.56 They found that hypoxic preconditioning was attenuated by 
a TNFa neutralising antibody suggesting a possible protective role for 
TNFa in this signalling. 
7. TNFa Signalling 
Tumour necrosis factor-alpha (TNFa) is an apical cytokine with a multitude of 
functions and has been implicated in the pathophysiology of various diseases. 
It is known that TNFa mediates processes like inflammation, cellular survival, 
growth, differentiation and apoptosis (Reviewed57,58). TNFa belongs to a 
family of signalling molecules that exist as type II membrane proteins 
characterised by the C-terminus being extra-cytoplasmic. TNFa receptors 
signal as homotrimers and can exist either as membrane-bound or as 
truncated soluble forms. Two distinct surface receptors mediate the effects of 
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TNFu namely TNF receptorJ (JNEH.1 or_p55) and TNF receptor 2-(TNFR2). ---- - - --1---------~ 
TNFR 1 is the main receptor subtype in most cells types including the heart 
and its complex and divergent downstream signalling systems have been 
extensively studied. The apoptotic signalling events subsequent to receptor 
clustering have been well defined for Fas and TNFR1. The coupling of the 
adapter Fas-associated death domain protein (FADD) to TNFR1 is associated 
with the recruitment and activation of apoptotic proteases with subsequent 
progression to programmed cell death. The transduction of signals from 
TNFR2 and its role in TNFu signalling remains less well characterised. 
TNFR2 is believed to activate TNF receptor associated factor 2 (TRAF2) that 
also couples to TNFR1. TRAF2 is believed to be a cytoprotective complex 
that activates both NFK B-dependent and - independent transcriptional events 
implicated in the induction of cytoprotective genes. These cytoprotective 
genes are involved in cellular growth, survival and proliferation. The 
cytoprotective pathways downstream of the TNFu receptors that may be 
relevant to the maintenance of cardiac homeostasis are protein kinases 
(PKC); stress activated protein kinases (SAPK) and downstream of c-Jun N-
terminal kinase (JNK). The putative TNFu mediated cardioprotective 
programmes against ischaemia-reperfusion injury may be downstream of 
PKC, NFK B and SAPK. Myocardial TNFu production has been well 
documented during acute ischaemia with or without reperfusion.59,60 It is 
believed that the acute TNFu induced reduction in contractility during acute 
ischaemic syndromes may be an additional adaptive action of this pleiotropic 
peptide. Mann and colleagues demonstrated the cardioprotective action of 
TNFu in an acute ischaemia model using receptor knockout mice.41 These 
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--------~m- ice_developed larger myocardial infarcts compare-d- to- w11a=type littermate 
controls when subjected to an acute infarction in vivo. This study 
demonstrated that TNFa signalling is required for endogenous myocardial 
resistance to ischaemic cell death through an unknown mechanism. In our 
laboratory we have demonstrated using genetically modified mice that the 
TNFa signalling cascade plays a role in the postnatal adaptive myocardial 
growth response to multiple biomechanical stresses.61 Moreover, 
pretreatment of rabbits with intravenous TNFa 24 hours before ex vivo 
simulated ischaemia and reperfusion resulted in improved cardiac contractile 
functional recovery and reduced lactate dehydrogenase release.50_ In our 
laboratory, Lecour et al have reported that pretreating isolated rat hearts with 
TN Fa (0.5 ng/ml) for 7 minutes followed by a washout of 10 minutes prior to a 
simulated ischaemic-reperfusion protocol resulted in a marked increase in 
recovery with the TN Fa group compared to the vehicle pretreated control. 62 
Collectively, these data suggest that the production of TNFa by the 
myocardium in response to an ischaemic and reperfusion insult may in fact be 
an endogenous pathway activated by the heart to induce short-term intrinsic 
cardioprotection against subsequent ischaemia-reperfusion injury. Supportive 
evidence in brain tissue demonstrates that TNFa plays a key role in ischaemic 
tolerance.56 The signalling mechanisms whereby TNFa may provide 
tolerance to ischaemia or to promote adaptive cardiac protection have, 
however, not been established. 
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1--------=8. l:fypothesis-----
Thus for this dissertation, we hypothesise that TNFa is an endogenous trigger 
of classic preconditioning. Moreover, we believe that investigation of 
TN Fa signalling may identify novel mechanism to enhance protection against 
ischaemic injury. To investigate the hypothesis we will undertake the following 
studies. 
9. Objectives 
• Delineation of the temporal and dose requirement of TNFa to promote 
protection against ischaemic injury; 






1. Establishment of cell lines to study TNFa as a ligand to induce 
preconditioning 
In order to evaluate our hypothesis and to interrogate the putative signalling 
cascade activated by TNFa in the heart, we began by using a cellular model, 
which simulated ischaemia and ischaemic preconditioning. We decided to 
perform our initial dose and temporal effects studies of TNFa in two cell lines 
that had previously been used for preconditioning studies i.e. mouse skeletal 
muscle cell line (C2C12)63 and a human cardiac derived cell line, Girardi cells 
(Hela characteristics).64 The C2C12 mouse cell line was subcloned from 
skeletal myotubes and was established by Yaffe and Saxel using hindlimb 
muscle.65,66 The C2C12 cell lines are rapid dividing myoblastic cells that 
with differentiation develop multinucleated myotubes and characteristically 
produce muscle peptides. The second cell line used was the Human derived 
Girardi cell line. These transformed cells were derived from a biopsy 
specimen of right auricular appendage of an adult human heart. The cell was 
found to have Hela profile after DNA fingerprinting . These cells have epithelial 
cell morphology and grow as adherent monolayers. 
2. Culturing of Cells 
Both cell lines were obtained from the European Collection of Cell Cultures 
(Centre for Applied Microbiology and Research, UK) and stored in Liquid N2. 
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To grow the cells, the cryovials were half immersed in 37-degree_water bath __ _ 
for 30-40 seconds. The content of the ampule was pipetted out into a 25cm3 
flask containing fresh culture medium. The cells were grown in these flasks 
until confluency was reached. The trypsin/EDTA solution contained 0.25% 
(w/v) Trypsin, 0.2% (w/v) EDTA and made up to volume with sterile 
phosphate buffer saline. The EDTA (disodium ethylenediamine tetraacetic 
acid) is a chelating agent to prevent the trypsin from binding to calcium and 
magnesium ions. The adherent cells were displaced by trypsin treatment and 
were then reseeded into secondary cultures. A cell passage constitutes the 
splitting of cells with trypsin following growth to confluence. When confluent, 
the cells were trypsinised with a trypsin / EDTA solution for 1-2 minutes in 37 
0c, 5% CO2 incubator. Sufficient trypsin was added to ensure the whole layer 
of cells was covered. Cell detachment was confirmed using light microscopy 
(Inverted microscopy). Following detachment, serum or medium containing 
serum was added to inhibit the trypsin activity. Excess exposure of cells to 
trypsin is deleterious and trysinisation should be limited to a maximum of 1-2 
minutes. The cells were then spun down in a centrifuge for 5 minutes at 1000 
rpm. The trypsin is then aspirated off and the cell pellet is resuspended in 
sufficient volume of media to split into either 1 :3 or 1 :4 depending on the size 
of flask/plates used. Cell numbers are determined by cell counting on a 
haemocytometer. The number of cells per millimeter = the average count of 
cells per square multiplied by the dilution factor multiplied by the factor 104 . 
The cells were plated to reach confluency in 24 to 36 hours. 
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3. C2C12 Cells 
The C2C12 myotubes are maintained in medium that consist of Dulbecco's 
modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1,5 g/L 
sodium bicarbonate, 4,5 g/L glucose and 1 ,0 mM sodium pyruvate and 10 % 
horse serum. The minimum seeding density for C2C12 cells is 20 x103 
cells/cm2. The doubling time for C2C12 is roughly 26 hours. Approximately 40 
x103 cells/cm2 constitute confluency. The C2C12 myotubes are split at a 
confluency of between 70-80% to prevent constitutive differentiation. To 
differentiate the cells into myotubes, the myoblasts media is changed to 2% 
horse serum when confluency reaches eg approximately 70-80%. The 2% 
horse serum replaces the foetal bovine serum. The C2C12 are only used 8-10 
days post differentiation. During the differentiation of the C2C12 myoblast, the 
cells are refed every three to four days. 
4. Girardi cells 
Girardi cell media consists of Minimal Essential Medium, 10% fetal bovine 
serum and 2 mM L-glutamine. The Girardi cells are grown to 100% confluency 
for experimental purposes or prior to splitting. The minimum seeding density 
is 20x103 cells/cm2• The doubling time for Girardi cells is 24 hours. When 
confluent the cell density is 160x103 cells/cm2. They are grown in Minimal 
Essential medium with 10% Fetal Bovine serum. After reaching confluency 
they are split for plating in flask or in plates for experimental purpose. 
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5. Cell Viability_Assays ___ _ 
5.1 LOH assay 
To study the role of TN Fa in protection we used lactate dehydrogenase (LOH) 
enzyme leakage into the media as one of the measurements of cell viability in 
all cell culture experiments.21,67 LOH measurements in the media were 
measured using the Roche Molecular Diagnostics kit (LOH SFBC cat. 
0736570). A control serum N (human) and control serum P was run 
concurrently with the experimental samples. Samples were run on the Cobas 
Mira spectrophotometer from Roche Diagnostics. Lactate dehydrogenase is 
the enzyme responsible for the conversion of lactate to pyruvate during 
aerobic conditions, and the reverse reaction during hypoxia. There are five 
LOH isoenzymes, and the rate of release of these enzymes into the blood 
stream is an indication of the degree of myocardial injury. 68 The samples are 
spectrophotometrically measured on the Cobas Mira at a wavelength of 340 
nm. 
5.2 Flow Cytometric Assessment of Propidium Iodide exclusion 
We also used propidium iodide exclusion as an index of cell viability.64,67 
Propidium iodide (Pl) is known to bind to DNA and become fluorescent. 
However, Pl cannot enter cells with intact cell membranes, and is hence 
included in immunofluorescent staining protocols to identify dead cells. The 
acronym FAGS (Fluorescene Activated Cell Sorting) and flow cytometry are 
used interchangeably. It works on the basis that individual cells held in a thin 
stream of fluid are passed through one or more laser beams causing light to 
scatter and fluorescent dyes to emit light at variuos frequencies . 
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Photomultiplier tubes (EMI )_convert light- te-electrical-signa1s ·ana-celf data is · 
1--------
c o I I e ct ed. At the end of the 8 hour ischaemic period, medium from each well 
was aspirated and saved . Cells were washed twice with warm PBS and then 
incubated for 2 minutes with 0.25% trypsin in 1mM EDTA. Detached cells 
were resuspended in the saved medium and then centrifuged at 3000rpm for 
4 minutes in a pre-cooled benchtop centrifuge at 4°C. The resulting cell pellet 
was then resuspended in ice-cold PBS, containing 1 µg/ml propidium iodide. 
The cell suspension was then immediately ru~ on a multichannel flow 
cytometer. The propidium iodide fluorescence was measured in a population 
of 1x104 cells and was expressed as percent change over ischaemic controls. 
6. Establishment of Protocol to Mimic lschaemia 
The first objective was to establish a simulated ischaemia protocol in both cell 
lines. The normoxic and hypoxic buffer were based on buffers devised by 
Esumi et aJ.69 The normoxic buffer consists of 137 mM NaCL, 3.58 mM KCI , 
0.49 MgCI , 0.9 mM CaCl2, 4 mM Hepes, 5.6 mM glucose and pH of 7.4. The 
hypoxic buffer was as follows: 137 mM NaCL, 3.58 mM KCI, 0.49 MgCI , 0.9 
mM CaCl2, 4 mM Hepes, and 20 mM 2-DG. The pH of the hypoxic buffer was 
adjusted to pH 6.4. 
7. Simulated lschaemia in C2C12 Cells 
Marban and colleagues found that the C2C12 myoblast could not be 
protected by preconditioning, however it was possible to precondition 
myotubes.63 Hence we used mature myotubes and the simulated ischaemia 
protocol was modified until the desired ischaemic insult could be obtained. 
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The o timal simulate_d_Jschaemia-was- ebtaineEJ--using- the- following pro oco 
(Fig.1.1 .): The control group was incubated in normoxic media throughout and 
maintained in a 5% CO2 incubator. The simulated ischaemia group had 
normoxic media for the first 2 hours followed by 8 hours of ischaemic buffer. 
During simulated ischaemia the plates were maintained in a hypoxic incubator 
(5% CO2, <1 % 0, 95% N2). The IPC group was initially exposed to 1 hour of 
SI and 1 hour of normoxia and a subsequent 8 hours in the hypoxic incubator. 
Cell viability was assessed using LOH release into the medium of the 
experiment in all the groups. The identical temporal conditions for stimulated 
ischaemia were employed when using the Girardi cells. Cell viability was 
assessed by LOH and propidium iodide exclusion assay. 
8. Protocol for IPC in C2C12 and Girardi Cells 
To induce IPC in the C2C12 cells, the cells were maintained under hypoxic 
conditions for 1 hour followed by an hour of exposure to normoxic media prior 
to the 8 hours simulated ischaemia period (see Fig 1.1). To induce IPC in the 
Girardi cells, the cells were maintained under hypoxic conditions for 30 
minutes followed by a 1 hour normoxia period prior to the 8 hours simulated 
ischaemia period (see Fig. 1.2). 
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Figure 1.1 ----------- --
Schematic representation of the protocols used in the C2C12 myotube study. 
All measurements of lactate dehydrogenase activity in the media were made 























































































































































































































































































Schematic representation of the protocols used in the Girardi cell study. All 
measurements of lactate dehydrogenase activity in the media were made at 
the end of the protocols as represented by the black arrows. To confirm cell 
viability the Pl exclusion assay was used and assess with FACS Analysis 



















































































































































9. Dose ancLiempo.-al-Effect-of TNFa-in-Promoting-cytoprotecfion - -
·-----___..::~=-=-~ 
Various TNFa concentrations were tested to evaluate the temporal 
requirements and dose effect to confer protection against ischaemic injury. 
The dose range was initially established from a literature search, which 
demonstrated the spectrum of survival or deleterious effects of TNFa. A dose 
response curve was set up that ranged from as low as 0.005 to 20 ng/ml 
TNFa. The cells were also incubated with the TNFa at various intervals. TNFa 
was incubated with cells as a PC mimetic, as a pretreatment and during 
hypoxia. After the ideal TNFa concentration was established, the cells were 
incubated with the desired dose as a pretreatment agent. It is the period prior 
to the eight hours hypoxia period. The cells were also incubated during the 
eight hours hypoxia with TNFa. The NFK B blockers were used along with the 
TNFa during the PC mimetic as well as during the pretreatment phase and 
the 8 hours hypoxic phase. Known pharmacological blockers of the IPC 
programme such as chelerythrine (PKC inhibitor), 5HD (mitochondrial KATP 
channel blocker) and glibenclamide (sarcolemmal and mitochondrial KATP 
channel blocker) were incubated together with TNFa or during the IPC 
protocol. 
10. Isolated Langendorff Perfused Rat Heart Model 
Once we established the optimal dose of TNFa as an IPC mimetic we then 
began to evaluate the signalling cascade downstream of TNFa in the isolated 
perfused rat heart preparation. We switched to the isolated heart due to its 
greater physiological relevance and due to the fact that it is ex-vivo versus the 
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.__ _ ___ ~in,_-v=it=ro c_elL sy_stem_ The- isolated- perfused -heart- apparatus- ased- was-· firsr 
described by Langendorff (1895), and later modified by Neely and co-workers, 
(1967).70 
Animal used: Male Long-Evans rats weighing 270-380 grams and fed a 
standard rat chow diet were used for all experiments performed in this study. 
All animals received care in compliance with the "Principles of Laboratory 
Animal Care" formulated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" prepared by the 
National Academy of Sciences and published by National Institutes of Health 
(NIM Publication No. 80-23, revised 1996). Rats were intraperitoneally 
anaesthetised with 0.35ml sodium pentobarbitone and then intravenously 
heparinised (200 IU) through the exposed femoral artery. The hearts were 
then rapidly excised, immersed in 4° C Krebs-Henselet buffer for transfer to 
the perfusion apparatus. Arrest was induced to afford the hearts maximal 
protection during the brief ischaemic episode during the transfer to the 
perfusion apparatus. The aorta was cannulated and perfusion re-established 
within 1 minute of excision from the donor animal. Hearts were retrogradely 
perfused at a constant pressure (100 cm H20) and temperature (37°C) with a 
modified Krebs-Henseleit buffer containing (mM) NaCl 118.5, NaHC03 25, 
KCI 4. 75, MgS04 1.19, KH2P04 1.18, CaCl2 1.36 and glucose 11. 
Oxygenation of the perfusion medium with 95% 0 2 and 5% CO2 resulted in 
PC02 of approximately 40 mmHg, P02 of approximately 550 mmHg and 
pH7.4. The pulmonary artery was incised to allow free drainage of the 
coronary effluent. Hearts were maintained at 37° C throughout the experiment 
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._ _ ____ y_ s_mrnunding- ttlem- witl:i- a--water- jaeketee chamber maintain-e-d- at- this 
temperature. A compliant balloon was inserted into the left ventricle to 
measure left ventricular end diastolic pressure, systolic pressure, heart rate 
and coronary flow. These functional parameters were recorded throughout the 
experiment using a pressure transducer which was connected to a Lectromed 
chart recorder or a computerised bridge amplifier / digitiser (Powerlab / 400, 
AD Instruments, Sydney, Australia), and continuously recorded using a 
Windows 95 operating system and Powerlab software. The criteria used for 
the inclusion of perfused rat hearts was a heart rate between 240-410 
beats/min, systolic pressure between 70-120 mmHg, end diastolic pressure of 
4-10 mmHg and a rate pressure product between 21 000-36 000 (mmHg 
beats/min)x103• In addition, only hearts with a coronary flow 8-18 ml/min were 
used.71 
11. Coronary Occlusion 
A 4/0 silk sature was placed around the left coronary artery, close to its origin 
and the hearts were threaded through the tip of a Gilson pipette to produce a 
snare and locked with a second pipette tip. Regional ischaemia was induced 
by carefully tightening the silk suture of the pipette against the epicardial 
surface; 30 minutes of regional ischaemia was followed by 120 minutes of 
reperfusion. Heart rate (HR) and left ventricular developed pressure 
(L VDP=difference between L V systolic and diastolic pressures) were 
continuously documented on the Lectromed recorder. Coronary flow was 
measured at regular intervals throughout the experiment. 
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12. The Perfusion Protocol 
The perfusion protocol is shown in Fig. 2. All hearts were allowed an 
equilibration period of at least 15 minutes and were consequently subjected to 
30 minutes of regional ischaemia followed by 120 minutes of reperfusion . No 
further interventions were performed in the controls. I PC was elicited by 2 
cycles of 5 minutes of global ischaemia interspersed with 5 minutes 
reperfusion prior to regional ischaemia. TNFa (0.5ng/ml) was given for 7 
minutes followed by 10 minutes of reperfusion washout before the regional 
ischaemia. DDTC and SA were given for 12 minutes, breaching the period of 
drug treatment with 2,5 minutes of antagonise pre-post TNFa administration 
(TNFa/DDTC and TNFa/SA). 
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Schematic representation of the protocols used in the isolated perfused heart 








































































































































































13. Measureme_nt_o_f_Risk-Zone and lnfarnt-Size· · -· · 
.__ _____ ..:..=..::...=.=..=c.=~~ 
Infarct size and area at risk were determined as done previously.72 At the 
end of the experiment, the silk suture around the coronary artery was securely 
tied and 0. 7 ml of a 2% Evans Blue suspension was slowly infused through 
the aorta to delineate the myocardial risk zone from the non-compromised 
zone. The hearts were then frozen overnight before being cut into 2-mm thick 
slices (four to five slices per heart), defrosted, and stained by incubation for 5 
minutes in 1 % w/v triphenyltetrazolium chloride (TTC) in phosphate buffer. 
Estimation of the infarct size was accomplished by means of planimetric 
comparison of myocardium, which had lost activity of the hydrogenase 
enzyme system with myocardium devoid of direct coronary artery perfusion. 
Tetrazolium dyes formed coloured precipitates in the presence of the intact 
dehydrogenase enzyme systems. Hence, viable myocardium was delineated 
by a bright red appearance, whereas areas of myocardial necrosis lacked 
dehydrogenase activity and therefore was devoid of staining. The necrotic 
areas were distinctly discernible and thus quantifiable. Slices were then fixed 
in 10% v/v formaldehyde solution to enhance the contrast between stained 
viable tissue and unstained necrotic tissue. The area at risk and the area of 
infarcted tissue in the risk zone were determined using computerised 
planimetry (Summa Sketch Ill; Summa Graphics). 
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14. PhosQhate Buffer for_I_TC_Staining--•---------' ------ ----- ---- - -
The phosphate buffer is made up of 2 solutions. Solution 1 is 1 OOmM 
Monobasic Sodium Phosphate (acidic): 15.6 g Na2P04.2H20 in 1 L dH20 or 
13.8 g NaH2P04.H20 in 1 L dH20. Solution 2 is 1 OOmM Dibasic Sodium 
Phosphate (alkaline): 14.2 g Na2HP04 in 1 L dH20. The Phosphate buffer is 8 
parts of solution 2 + 2 parts of solution 1 . 250 mg of TTC is added to 25 ml of 
phosphate buffer to make the staining buffer. 
15. Drugs 
Diethyldithiocarbamate (DDTC), Sodium Salicylate (SA), Triphenyltetrazolium 
(TTC), Evans Blue (Direct Blue) were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). TNFa was purchased from PeproTech Inc Rocky Hill, 
NJ . TN Fa was aliquated into 10 µg/ml stocks and kept frozen. Fresh TN Fa 
was used for all experiments from frozen stocks. TNFa stability is fairly robust, 
however fresh stocks are used on a daily basis due to progressive 
degradation at room temperature. 5HD was made up fresh for each new 
experiment. Final concentration of 1 OOµM of 5HD was prepared either with 
normoxic media / hypoxic media when it was used in cell culture experiments 
or with Krebs-Henselet buffer for the Langendorff perfusions. 
16. Statistical Analysis 
All data are presented as mean±S.E.M. Physiological variables were 
compared before and during coronary occlusion. The one-way analysis of 
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variance ANOVA) was_usedJo-determir:ie-si§nifieanee-between-groups in tne 







- ----- - - - -------- --- - - ---- - - - -
C.RESULTS 
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_____ C._RES_ULIS~--- ------ -------
1. Simulated lschaemia 
The first objective was to establish a simulated ischaemia protocol in both cell 
lines. As mentioned before, the C2C12 cells are more susceptible to 
ischaemic damage when they reach the mature myotube stage. We used 8-
10 days post differentiated C2C12 myotubes in all the experiments. The 
Girardi cells were used at a confluency of 100%. Simulated ischaemia was 
initiated by incubating the cells with a hypoxia buffer at pH 6.4 in hypoxic 
chamber (5% CO2. 95% N2). 8 hours ischaemia resulted in significant damage 
to the cells. 
Fig. 3.1 , Fig 3.2 and Fig 3.3 show the ischaemic insult on the C2C12 and 
Girardi cells. Measurement of Cell viability was evaluated by 
spectrophotometrical measurement of LOH and via the measurement of 
propidium iodide uptake on flow cytometry. The more severe the cell damage 
the higher the release of LOH into the media and higher the propidium iodide 
(Pl) uptake. The LOH and Pl data has been normalised to ischaemic control= 
100% percent damage value. This was done to enable comparisons across 
multiple experiments over a long time period. The 8 hour ischaemic insult 
causes around 60% increase in LOH release in both cell lines. The 
normalised data shows the normoxic values at 45±4 and 31±1 for the C2C12 
and Girardi cells respectively. Concomitantly the Pl data for the Girardi cells 
shows that there is a 95% increase in Pl positive cells in response to 8 hour of 
simulated ischaemia. 
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Figure 3.1 ------- --------
Effect of an ischaemic insult (8 hours) on lactate dehydrogenase (LOH) 
release in C2C12 myotubes. Data is normalised to the ischaemic insult group 





















































































































• ______ F_igure 3.2 ----------- ---
Effect of an ischaemic insult (8 hours) on lactate dehydrogenase (LOH) 

























































































































Fi ure 3.3 --------
Effect of an ischaemic insult (8 hours) on propidium iodide (Pl) positive cells. 
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2. lschaemic Preconc:Jjti_oningJn_c2c12 and-Girardi- - - -------- -
Previous reports have shown that preconditioning could be cell-type 
specific. 63 Our second objective was to investigate whether the two cell lines, 
could be preconditioned, using the system described in the Method Section. 
Here, preconditioning was achieved by exposing the cell to a sublethal 
ischaemic insult and reoxygenation prior to a sustained ischaemic insult. The 
optimal preconditioning protocol was slightly different in each cell line. The 
slightly different protocol confirms Marban· s findings on cell-type specificity of 
' preconditioning. The Girardi cells were more susceptible to ischaemic 
damage. The trigger ischaemic period was only 30 minutes compared to the 
60 minutes of the C2C12 cells. However a 60 minute reperfusion/normoxic 
period prior to the eight hours ischaemia was applied to both. The trigger 
ischaemia buffer pH was slightly lower than the index ischaemia (eight hours) 
buffer. We used an ischaemia buffer of pH 6.2. Fig. 4.1, Fig. 4.2 and Fig 4.3 
illustrate that the C2C12 and Girardi cells can be preconditioned using the 
respective protocols. IPC reduced cell damage (LOH release) by nearly 50%. 
LOH release was 53±3 and 57±1 % respectively for the C2C12 and_ Girardi 
cells. Our preconditioning protocol achieved the desired cytoprotection. There 
was, however, a bigger difference in the LOH release in the Girardi cells than 
in the C2C12 cells. As a confirmatory experiment, Pl exclusion was assessed 
in the Girardi cells. As shown in Figure 4.3 the ischaemic preconditioning 
protocol attenuated Pl uptake by 28±5% vs ischaemic controls. 
72 
Figure 4.1 •------~ 
Effect of ischaemic preconditioning (IPC) on lactate dehydrogenase (LOH) 
release following an ischaemic insult (8 hours) in C2C12 myotubes. Data is 


























































































































Effect of ischaemic preconditioning (IPC) on lactate dehydrogenase (LOH) 
release following an ischaemic insult (8 hours) in Girardi cells. Data is 




















































































































Effect of ischaemic preconditioning (IPC) on propidium iodide (Pl) positive 
cells following an ischaemic insult (8 hours) in Girardi cells. Data is 








































































































3. Attenuation of IPC in C2C_12_and-Girardi-Gells-
The preconditioning phenomenon has been described for the last 14 years. 
The development of specific and non specific blockers of the preconditioning 
programme has been identified. 5-hydoxydecanoic acid (5HD) is one of the 
most used preconditioning blockers. 5HD is a specific blocker of the 
mitochondrial KATP channel. Mitochondrial KATP channels are thought to be 
pivotal effectors in the protective cascade induced by preconditioning. 5HD 
has been shown to block IPC in various species. Fig 5. 1 and Fig 5.2 
demonstrate the effect of the known preconditioning blockers on the IPC 
groups in both cell lines. Adenosine, a known preconditioning agent, could 
also precondition the Girardi cells. The preconditioning blockers attenuated 
the cytoprotection of IPC in both cell lines. The 1 OOµM 5HD does not fully 
block/inhibit the protective effect. In previous studies we found that 1 mM was 
toxic to the cells. Glibenclamide blocks both sarcolemmal and mitochondrial 
KATP channels, also attenuated the protection when used with the C2C 12 
cells. Our results thus confirm that classical preconditioning is possible in our 
two cell lines and that the cytoprotection achieved through our protocol might 
follow the signalling pattern that is widely accepted at the moment. Although 
the underlying mechanism of ischaemic preconditioning is still not fully 
understood, evidence obtained through pharmacological studies suggests that 
adenosine receptors, protein kinase C and KATP channels are involved. 
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Figure 5.1 1--- ----~ - - - ---- ------ ---
Effect of the KArP channel blockers glibenclamide (100 µM) and 5-
hydroxydecanoate (5HD; 1 OOµM) on ischaemic preconditioning (IPC) as 
measured by lactate dehydrogenase (LOH) release following an ischaemic 
insult (8 hours) in C2C12 myotubes. Data is normalised to the ischaemic 







































































































Figure 5.2 ---- ----------- -
Effect of the mitochondrial KATP channel blocker 5-hydroxydecanoate (5HD; 
100 µM) on ischaemic preconditioning (IPC) and the effect of pre-treatment 
with adenosine (100 µM) as measured by lactate dehydrogenase (LOH) 
release following an ischaemic insult (8 hours) in Girardi cells. Data is 
normalised to the ischaemic insult group (100%; n ~ 6; * p<0.05 vs lschaemic; 

















































































































______ 4~._T...:....:....:.N.:....F=a.-"'a=s_,.a~P~C_mimetic-Agent-------- -~-·- --~-~ 
After establishing a cellular model of preconditioning with the two cell types, 
we then investigated the temporal and dose requirements of TNFa. in 
promoting protection against ischaemic injury. TNFa. was initially used as a 
preconditioning mimetic using a dose ranging from 0.005 ng/ml to 20 ng/ml in 
both cell lines. The PC mimetic protocol for TNFa. was similar to the IPC 
protocol for both cell line respectively (see Fig 1.1 and Fig 1.2). In Fig 6.1 , 6.2 
and 6.3 we clearly demonstrate that a 0.5 ng/ml TNFa. is cytoprotective for 
both cell lines. TNFa. induced cytoprotection(LDH release) by nearly 40% in 
both cell lines compared to ischaemic controls. Using propidium iodide 
exclusion as an additional index of cell viability, we have confirmed that the 
optimal dose of TNFa. does attenuates Pl uptake by 42±5% vs ischaemic 
controls (p<0.001) when TNFa. was administered as a preconditioning mimetic 
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Figure 6.1 --- - -- ------ ---- -------·---
Effect of recombinant TNFa (0.5 ng/ml) pre-treatment (1 hour exposure 
followed by 1 hour wash off) on lactate dehydrogenase (LOH) release in 
C2C12 myotubes following an ischaemic insult (8 hours). Data is normalised 
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Figure 6.2 --------- - -------
Effect of recombinant TNFa (0.5 ng/ml) pre-treatment (30 minutes exposure 
followed by 1 hour wash off) on lactate dehydrogenase (LOH) release in 
Girardi cells following an ischaemic insult (8 hours). Data is normalised to the 








































































































Effect of recombinant TNFa (0.5 ng/ml) as a preconditioning-mimetic (1 hour 
exposure followed by 1 hour wash off) on propidium iodide (Pl) positive cells 
in Girardi cells following an ischaemic insult (8 hours). Data is normalised to 
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11n- Fig-7. 1 and-1:2-the- dose response of Tf\JFa on the two cells is presented. 
The cytoprotective doses of TNFa range from 0.005 to 0.5 ng/ml. Doses that 
were cardiotoxic ranged from 5.0 ng/ml up to 20 ng/ml. The transition from 
being cytoprotective to deleterious to the cell is between 0.5 ng/ml and 5 
ng/ml. There is a 60% increase in LOH release between 0.5 ng/ml and 5.0 
ng/ml. (0.5 ng/ml=60±1, 5.0 ng/ml=123±5). We did not go higher than 5 ng/ml 
with the C2C12 cells as the dose effect seen for 0.005-5.0-ng/ml mirrored that 
established in the Girardi cells. It is clearly evident that lower (physiological) 
doses of TNFa are cytoprotective in both these two cell lines. The higher 
(supraphysiological) doses are detrimental to the cell. 
91 
Figure-7.1 
Effect of increasing dose of TNFa (0.005 - 5.0 ng/ml) pre-treatment (1 hour 
exposure followed by 1 hour wash off) on lactate dehydrogenase (LOH) 
release in C2C12 myotubes following an ischaemic insult (8 hours). Data is 



























































































































































Effect of increasing dose of TNFa (0.005 - 20,0 ng/ml) pre-treatment (30 
minutes exposure followed by 1 hour wash off) on lactate dehydrogenase 
(LOH) release in Girardi cells following an ischaemic insult (8 hours). Data is 


































































































































































































5~ Tem-poral Effects~of TNFaAclmimstration 
TNFa PC mimetic abilities afford cytoprotection in both cell lines. The next 
step was to investigate the temporal effects of this cytokine to see if it can 
protect the cells against ischaemic damage. For the temporal studies we 
incubated both cell lines with 0.5 ng/ml TNFa during the one hour reperfusion 
(pretreatment), before the eight hours ischaemic period as well as during the 
eight hours ischaemic period (hypoxia). Fig. 8.1 and Fig. 8.2 demonstrate the 
temporal effect of 0.5 ng/ml TN Fa as seen with the two cell lines. In the 
Girardi cells there is a cytoprotective effect of TNFa in both pretreatment as 
well as in the eight hours ischaemic period. It seems that TNFa also has an 
anti-ischaemic property. In the C2C12 cells the TN Fa does not have a 
cytoprotective effect, as the LOH release is nearly the same as the ischaemic 
control (91±5). The TNFa was also incubated with a normoxic control and had 
no appreciable effects. The unique cytoprotection cantered by TNFa is clearly 
demonstrated here in Fig 8.1 and 8.2. However, there is no explanation for 
the detrimental effects of 0.5 ng/ml TNFa in the eight hours hypoxic/ischaemic 
period. Being a PC mimetic agent, pretreatment agent and an anti-ischaemic 
agent in these cells support the concept that TNFa may be favourable 
cytoprotective agent. 
96 
----Figure-8.1 : - --
Temporal effects of TN Fa on lactate dehydrogenase (LOH) release in C2C12 
myotubes following an ischaemic insult (8 hours). The treatment groups are 
as follows: TNFa (0.5 ng/ml) pre-treatment (1 hour exposure followed by 1 
hour wash off); TNFa (0.5 ng/ml) pre-treatment (1 hour exposure wash off 
immediately prior to the ischaemic insult) and TNFa (0.5 ng/ml) exposure 
during the ischaemic insult. Data is normalised to the ischaemic insult group 

















































































































































Temporal effects of TNFa on lactate dehydrogenase (LOH) release in Girardi 
cells following an ischaemic insult (8 hours). The treatment groups are as 
follows: TNFa (0.5 ng/ml) pre-treatment (30 minutes exposure followed by 1 
hour wash off); TNFa (0.5 ng/ml) pre-treatment (1 hour exposure wash off 
immediately prior to the ischaemic insult) and TNFa (0.5 ng/ml) exposure 
during the ischaemic insult. Data is normalised to the ischaemic insult group 































































































































































6: Attenuation of IP-C and T)fF-abiNFx B Antagonists 
The cytoprotective ability of IPC has been studied extensively and is still 
ongoing. The elucidation of the signalling pathway involved in the cellular 
protection of IPC needs further investigation. It was recently being suggested 
that a transcriptional activator might be involved in the cytoprotection induced 
by IPC. Transcriptional activation might be an important step as it has been 
found that using agents like cyclohexamide and actinomycin D could abolish 
the cytoprotection of SWOP.4 Bolli recently showed that the transcriptional 
activator NFx B might be an important mediator in the signalling of IPC. He 
used a NFK B blocker (DDTC) in his IPC experiments.4 DDTC abolished the 
cytoprotection of IPC on experiments with rabbits. Thus, we investigated the 
signalling pathway involved in TNFa cytoprotection. As TNFa and IPC 
mediated more or less the same percentage of cytoprotection in our cellular 
model we proposed that they might share common signalling pathways in 
their protection. We then set up experiments by using two NFK B blockers 
along with the IPC and TNFa group. The additional NFK B blocker we used 
was sodium salicylate (SA).73 The two blockers were incubated along with 
the IPC trigger and PC mimetic period respectively. In Fig. 9.1 and 9.2 we can 
clearly demonstrate that the protection of both IPC and 0.5 ng/ml TNFa were 
attenuated by the two NFK B blockers. This data suggest that the IPC and 
TNFa might share a common cytoprotective pathway. It is also shown that the 
cytoprotection is the same in both cell lines. It seems the transcriptional 
activator NFK B plays an integral mediator role in the protection signalling 
system of IPC and TNFa. 
101 
Figure-9.1 
Effect of NF-KB inhibition by salicylic acid (10 mM) and diethyldithiocarbamate 
(DDTC; 10 mM) on ischaemic preconditioning (1 hour simulated ischaemia 
and 1 hour reperfusion prior to the index ischaemia) and TNFa (0.5 ng/ml) 
pre-treatment (1 hour exposure followed by 1 hour wash off) on lactate 
dehydrogenase (LOH) release in C2C12 myotubes following an ischaemic 
insult (8 hours). Data is normalised to the ischaemic insult group (100%; n ~ 
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Effect of NF-KB inhibition by salicylic acid (10 mM) and diethyldithiocarbamate 
(DDTC; 10 mM) on ischaemic preconditioning (1 hour simulated ischaemia 
and 1 hour reperfusion prior to the index ischaemia) and TNFa (0.5 ng/ml) 
pre-treatment (30 minutes exposure followed by 1 hour wash off) on lactate 
dehydrogenase (LOH) release in Girardi cells following an ischaemic insult (8 
hours). Data is normalised to the ischaemic insult group (100%; n ~ 6; *p<0.05 











































































































































































7-: Infarction-of IPC and TNFa-versus NFK B Anta-gonists 
We then moved to the Langendorff perfusion apparatus to continue the study 
of the effect of TNFa on the rat heart. The cellular model we used identified 
the dose and temporal requirement of TNFa. The perfusion protocol for the 
isolated rat heart is illustrated in Fig. 2. We made use of LOH release as 
marker of cell damage in the cell culture model. In the rat heart perfusion 
model we made use of infarct size as the marker of cell damage. Our previous 
study suggested that IPC and TNFa might share a common mediator in the 
form of NFK B in their cytoprotective effects. By shifting the system to an ex 
vivo model, we can clearly establish if TNFa and IPC share common 
signalling mediators. The TNFa PC mimetic protocol was establishes by a 
fellow colleague. We perfused the hearts with TNFa or with TNFa plus DDTC 
and SA. DDTC and SA were perfused alone to evaluate if they were toxic to 
the hearts. Figure 10 demonstrates that TNFa cytoprotection can be 
abrogated by co-administration of the two NFK B antagonists DDTC and SA. 
Our infarction data therefore support the involvement of NFK B cytoprotective 
cascade of TN Fa signalling. 
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Figure-10 
Effect of NF-KB inhibition by salicylic acid (10 mM) and diethyldithiocarbamate 
(DDTC; 10 mM) on ischaemic preconditioning (cycles of 5 minutes global 
ischaemia followed by 5 minutes of reperfusion prior to the index regional 
ischaemia) and TN Fa (0.5 ng/ml) pre-treatment (7 minutes followed by 10 
minutes washout) on 30 minutes regional ischaemia (index ischaemia) 
followed by 2 hours reperfusion in the Langendorff perfused rat heart. Infarct 
size is expressed as a percentage of the area at risk. All values mean + 





































































































































The major findings demonstrate that TNFa. administration at physiological 
doses promotes protection against ischaemic injury in transformed cell lines 
and in the isolated perfused rat heart. TNFa. activates this survival phenotype 
when administering as a PC 'trigger', as pretreatment, or if administered 
directly during ischaemic insult in the two cell lines studied. Finally, TNFa.'s 
protection seems to act via classical ischaemic preconditioning mediated 
signalling and may be activated, in part, via the transcriptional regulatory 
peptide NFK B. 
1. Dose and Temporal Effect of TNFa. in PC in Cells 
A dose response for TNFa. induced preconditioning was initially determined. 
TNFa. was shown to protect the cells against an ischaemic insult when 
administered at dosages ranging from 0.005 to 0.5 ng/ml. Higher doses were 
shown to be detrimentai.74 These data are consistent with studies in various 
cell types in which TNFa. doses of 5.0 ng/ml up to 20.0 ng/ml have been 
implicated to be pro-apoptotic. Sack and colleagues have proposed the 
concept of physiological versus supraphysiological dose effects and state that 
the concentration of TNFa. interacting with myocardial cells may also 
determine its homeostatic effect.58 Nutt et al and Edmunds et al have 
illustrated the concept regarding contractile function by demonstrating that in 
the ex vivo heart cardiac contractile function is markedly attenuated at higher 
110 
concentrations of fNF~ infusions (i.e. 20 ng/ml).75,76 In a similar st~dy by 
Yokoyama et al the concentration effect of TNFa is demonstrated in that it 
partially inhibited the phosphorylation of phospholamban and of troponin 1.77 
We then evaluated the temporal requirement of TNFa in the two cell lines 
studied. The temporal effects were assessed using the optimal dose of TNF 
ie. 0.5 ng/ml. The TNFa concentration of 0.5 ng/ml had cytoprotective effects 
when administered as a PC trigger and as pretreatment in the two cell lines. 
Moreover, in the Girardi cells TNFa has a cytoprotective effect during the 
ischaemic insult. The temporal protective effect of TNFa suggests that it may 
act as a PC mimetic agent and that this cytokine may have anti-ischaemic 
properties. The latter finding is supported by the work of Mann and colleagues 
who demonstrated that the genetic ablation of both TNFa receptors subtypes 
in mice exposed to ischaemia in vivo, developed larger infarcts compared to 
wild-type control mice.41 
2. Signalling with Classical IPC 
Classical preconditioning results in an increased resistance to cell injury that 
follows short sublethal periods of ischaemia. A variety of intracellular 
signalling pathways have been implicated in the protective mechanism of IPC. 
These include the activation of G-protein-linked phospholipase C- coupled 
receptors, tyrosine kinase pathways, protein kinase C (PKC) and the 
generation of reactive oxygen species.16 The protection confered by IPC can 
be blocked at several steps in each cascade. Activation of the mitochondrial 
111 
KATP channels is-thought to be a-pivotal intracellular event-in-orchestrating this-
protection. In our cellular model we used two KATP blockers namely 
glibenclamide and 5 hydroxydecanoate (5HD) to see if we can block IPC 
cytoprotective effect. The IPC was attenuated in both the C2C12 and the 
Girardi cells by glibenclamide and 5HD. Glibenclamide is however both a 
sarcolemmal and mitochondrial KATP channel inhibitor. Substantial evidence 
has accumulated in support of mitoKATP as a late effector of cardioprotection 
and this has shifted the focus on how the opening of a K+ influx pathway on 
the inner mitochondrial membrane may be protective. Three main mechanistic 
hypotheses have been proposed to explain the protective effect of mitoKATP 
channel opening: 
• Mitochondrial swelling and optimisation of Respiration 
• Mitochondrial Ca2+ Handling and 
• Free radicals and Redox state. 
These are not explored in this current body of work. 
3. Potential novel signalling 
IPC and TNFa have similar cytoprotective effects, as is evident from their 
similar attenuation in LOH release in the two cell lines. Moreover, IPC and 
TNFa cytoprotection could be blocked by mitoKATP channel inhibitors. These 
observations raise the question if there is a common mediator upstream of the 
mitochondrial KATP for IPC and TNFa. In this regard NFKB is the first 
transcriptional regulator that has been identified as an integral component of 
the late PC.4 NFK B is known to be a major modulator of iNOS, COX-2 and 
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aldose- reauctase gen~e- expression. Xuan et al has de-m-onstrated thaf 
ischaemic PC induces a rapid activation of NFKB in rabbits. Li and colleagues 
have reported that NFK B is upregulated in rat hearts subjected to short-term 
protocols of ischaemia/reperfusion in vivo and in vitro.78 TNFa is known to 
induce NFKB activation in various tissues and cells. NFK B activation by TNFa 
is via TRAF2. In this body of work we demonstrate that by using two NFKB 
blockers we attenuate the cytoprotective abilities of TNFa and IPC in both cell 
lines and in the isolated perfused rat heart. This suggests that both lPC and 
TNFa cytoprotection may be mediated via NFKB in our models of 
preconditioning. 
4. Limitation of Cell Culture Model 
Cell based models have certain advantages that make them useful in 
ischaemic reperfusion experiments. Some of the advantages are small 
volume of distribution, an ability to manipulate signalling proteins by 
introduction of cDNAs, antisense RNA, recombinant protein, interfering 
peptides and through the interrogation of altered signalling cascades and their 
consequence within a homogeneous cell type. These advantages are at the 
expense of a cell phenotype that differ from the intact heart and cannot be 
subjected to true ischaemia/reperfusion. The mechanisms may thus not 
reflect those in vivo. Another major differentiation factor between the cells and 
the in situ heart is the fact that their ischaemic periods differ from each other. 
lschaemic preconditioning triggers in in-vivo and ex-vivo hearts last for about 
5 minutes, but range from 30 minutes (Girardi cells) to 1 hour (C2C12 
113 
myotub-es) in th-e-cell lines~ Th-es-e- vast differences can p-o-ssibl~F extena wnar 
would be post-translational events in the heart into pre-translational events in 
the cells. Thus, it may be possible that the cytoprotection demonstrated in 
cells may be more relevant to delayed protection or may have a hybrid of 
regulatory events that span both windows of protection. In addition, cells 
feeding and growing result in morphological and metabolical changes. These 
factors might be an additional stress activated or preconditioning effect 
response on the cells. The C2C12 cells have a change in food substrate and 
it might be argued that the preconditioning effect in them might be second 
window related. It has previously been shown that serum deprivation can 
have a cytoprotective effect on the cells. In addition neither C2C12 nor the 
Girardi cells are true cardiac cells. The Girardi's are Hela type of cells and the 
C2C12 are skeletal muscle cells. This gives rise to the question as to whether 
the cellular mechanism of these two cell lines are relevant to the cardiac cell. 
The other factor that makes the two transformed cell lines different from 
cardiac cells is that they cannot contract. The contractility process is a very 
important biological process for cardiac cells and hence the morphology, 
enzymes and proteins differ in comparison to the transformed cells. 
5. Confirmation in Perfused Hearts 
To confirm TNFa: s effect in the cardiac tissue, the experiments were then 
repeated in the isolated perfused rat heart. The isolated heart has greater 
physiological relevance and also for the fact that it is ex-vivo vs the in vitro 
transformed cell system. In the isolated rat heart other tissue come into the 
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pictuTe- likef smtfoth- mus-c1e- cellff, myocytes, blood vessels~-connective tissue 
and fibroblasts . All the tissues play an integral role in the heart and have the 
ability to release certain paracrine factors that may affect their overall 
biological effects. The isolated heart thus has various tissue structures 
compared to the transform cell lines. The main observation with the isolated 
heart was that the optimal TNFa (0.5 ng/ml) had the same cytoprotective 
abilities as it had in the cell lines. The infarction data confirms that TNFa 
signalling is also relevant to infarct size reduction effects of this cytokine. The 
dose 0.5 ng/ml confirms our hypothesis that the physiological dose is 
cytoprotective for both cell lines and ex-vivo contractile rat heart tissue. After it 
was found that TNFa could precondition the cells we investigated whether the 
cytoprotection might be via similar signalling paths. We used the same doses 
of the NFK B inhibitors. DDTC and SA attenuated the PC mimetic 
cytoprotection in the isolated heart as confirmed by the increased infarct size 
when TNFa signalling was blocked by these agents. Thus a potential 
cytoprotective role might exist for TNFa in the cellular mechanism in variety of 
cell and tissue types. 
6. Mode of Action 
TNFa's mode of action that results in cytoprotection may follow a similar path 
as IPC. Whether this is true has to be further elucidated. As TNFa 
cytoprotection could be blocked by various IPC blockers, our data suggest 
that IPC and TNFa might have similar signalling pathways. 
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7. Limitation of Study Coupled to the Future Aims 
The tissue culture experiments need careful attention and the cells could not 
be used after a few passages. With each passage the phenotypic 
characteristics of the cells decreased. The innate mechanism of myocardial 
protection has generated considerable excitement and enthusiastic research. 
The molecular mechanisms and the full elucidation of the signalling events 
are not fully understood yet. The positive side of isolated cells are the fact that 
they are more resilient, available and transfection permissive. The addition of 
mitosis and transfection with selectable markers allow the formation of stable 
cell lines. The draw back of the different cell lines is the inconsistent 
preconditioning. More and more evidence supports the contribution of KArP 
channels and kinase pathways in this cytoprotective process. The full detail of 
the process is however still to be determined and this is mostly achieved in 
isolated cells. Other models and tools should be developed to address certain 
questions and a combination of techniques are needed to confirm the 
mechanistic process derived from isolated cells that would also reflect the 
mechanistic process in vivo. The same approach that will be taken to address 
the complete signalling pathway of IPC could and should also be utilised to 
study TNFa in cytoprotection. The molecular mechanisms conferring these 
putative adaptive events by TNFa are still unknown and need to be 
investigated. Also to further explore the involvement of NFK B in TNFa 
induced cardiac protection we would like to confirm the role of NFK B using 
gene ablation techniques and the delineation of the NFK B activated genes 
promoting cell survival. More investigation will be conducted with particular 
reference to the temporal activity of the cytokine in response to different 
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p-athol5hysiological events- c:mcrth-e- putative diverg~enrpatnways leading eifher 
to cardiac protection or to apoptosis. The pharmacologic antagonists used in 
this and other studies have limitations in that they are not complete specific. 
Regarding this study, the molecular characterisation of the mitochondrial KArP 
channel is incomplete and the specificity of 5-HD is unknown. Moreover SA is 
known to have additional function eg. to block prostaglandin metabolism while 
DDTC is also known to inhibit the Cu-Zn SOD. Thus all the data derived from 
these pharmacologic antagonist studies need to be evaluated using different 





In conclusion TNFa when administered at physiological levels mimics the 
cytoprotective effects of ischaemic PC in cardiac and skeletal myocytes and in 
the isolated perfused rat heart. TNFa activates this cytoprotective programme 
when administered as a PC trigger as pretreatment and if administered 
directly during the ischaemic insult in the cell lines. These data are additional 
evidence to support the functional role of the innate immune system in 
improving cell survival in non-meyoloid tissue. 
In addition, as the pharmacologic studies suggest that NFK B signalling is 
important in this cell survival programme, we need to explore and characterise 
the downstream targets of this nuclear regulatory peptide to further advance 
our understanding of the innate cytoprotection. The cytoprotective properties 
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